Amonafide (Synonyms: 氨萘非特; AS1413)

目錄號(hào): HY-10982 純度: 99.92%: FAQs
Data Sheet SDS COA 產(chǎn)品使用指南技術(shù)支持

Amonafide 是一種拓?fù)洚悩?gòu)酶 II (topoisomerase II) 的抑制劑和 DNA 的嵌入劑，通過抑制 Topo II 與 DNA 的結(jié)合，來誘導(dǎo)凋亡信號(hào)通路的發(fā)生。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

Amonafide Chemical Structure

CAS No. : 69408-81-7

1. 客戶無需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2. 同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3. 試用裝只面向終端客戶。

規(guī)格	價(jià)格	是否有貨
10 mM * 1 mL in DMSO	￥737	In-stock
1 mg	￥268	In-stock
5 mg	￥669	In-stock
10 mg	￥837	In-stock
25 mg	￥1758	In-stock
50 mg	￥2790	In-stock
100 mg	￥4669	In-stock
200 mg		詢價(jià)
500 mg		詢價(jià)

or 大包裝詢價(jià)

* Please select Quantity before adding items.

Customer Review

Other Forms of Amonafide:

Amonafide dihydrochloride 詢價(jià)

MCE 顧客使用本產(chǎn)品發(fā)表的 3 篇科研文獻(xiàn)

•ACS Appl Mater Interfaces. 2021 Nov 16. [Abstract]
•Anal Chem. 2022 Mar 8. [Abstract]
•Cancer Manag Res. 2019 Mar 22;11:2339-2348. [Abstract]

Amonafide 相關(guān)產(chǎn)品

•相關(guān)化合物庫(kù):

•同靶點(diǎn)產(chǎn)品:

•同靶點(diǎn)蛋白產(chǎn)品:

查看 Topoisomerase 亞型特異性產(chǎn)品:

查看所有亞型

Topoisomerase Topo I Topo II

生物活性
實(shí)驗(yàn)參考方法
純度 & 產(chǎn)品資料
參考文獻(xiàn)

生物活性

Amonafide is a topoisomerase II inhibitor and DNA intercalator that induces apoptotic signaling by blocking the binding of Topo II to DNA.

IC₅₀ & Target^[1]

Topoisomerase II

細(xì)胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A 172	GI₅₀	> 25 μM Compound: AM	Growth inhibition of human A172 cells preincubated for 6 hrs followed compound washout measured after 24 hrs by XTT assay Growth inhibition of human A172 cells preincubated for 6 hrs followed compound washout measured after 24 hrs by XTT assay	[PMID: 28710962]
A 172	GI₅₀	> 25 μM Compound: AM	Growth inhibition of human A172 cells preincubated for 6 hrs cotreated with chlorambucil followed compound washout measured after 24 hrs by XTT assay Growth inhibition of human A172 cells preincubated for 6 hrs cotreated with chlorambucil followed compound washout measured after 24 hrs by XTT assay	[PMID: 28710962]
A 172	IC₅₀	23.81 μM Compound: Amonafide	Cytotoxicity against human A 172 cells assessed as cell viability measured after 96 hrs by XTT assay Cytotoxicity against human A 172 cells assessed as cell viability measured after 96 hrs by XTT assay	[PMID: 34507011]
A2780	IC₅₀	11.66 μM Compound: Amonafide	Antiproliferative activity against human A2780 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human A2780 cells assessed as cell growth inhibition by MTT assay	[PMID: 36894107]
A-375	IC₅₀	14.7 μM Compound: B2	Cytotoxicity against human A375 cells in hypoxic condition after 24 hrs by MTT assay Cytotoxicity against human A375 cells in hypoxic condition after 24 hrs by MTT assay	[PMID: 17331719]
A-375	IC₅₀	7.51 μM Compound: Amonafide	Cytotoxicity against human A375 cells by MTT assay Cytotoxicity against human A375 cells by MTT assay	[PMID: 19643513]
A549	IC₅₀	1.1 μM Compound: Am	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 23353750]
A549	IC₅₀	1.1 μM Compound: B2	Cytotoxicity against human A549 cells by sulforhodamine B dye staining method Cytotoxicity against human A549 cells by sulforhodamine B dye staining method	[PMID: 17331719]
A549	IC₅₀	1.59 μM Compound: Amonafide	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	10.1039/C5MD00543D
A549	IC₅₀	1100 nM Compound: amonafide	Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B dye assay Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B dye assay	[PMID: 17707644]
A549	IC₅₀	1100 nM Compound: 1	Tested for inhibitory activity against human tumor cell line A549 (a non small, drug resistant cell line that does not produce P-glycoprotein) of lung carcinoma using sulforhodamine B assay. Tested for inhibitory activity against human tumor cell line A549 (a non small, drug resistant cell line that does not produce P-glycoprotein) of lung carcinoma using sulforhodamine B assay.	[PMID: 10956214]
A549	IC₅₀	1100 nM Compound: Amonafide	Cytotoxic concentration against human A549 lung cancer cell line determined by sulforhodamine B dye-staining method Cytotoxic concentration against human A549 lung cancer cell line determined by sulforhodamine B dye-staining method	[PMID: 15876532]
A549	IC₅₀	13 μM Compound: Amonafide	Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 24370011]
A549	IC₅₀	13 μM Compound: Amonafide	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 19643513]
A549	IC₅₀	13 μM Compound: amonafide	Growth inhibition of human A549 cells by SRB assay Growth inhibition of human A549 cells by SRB assay	[PMID: 17532640]
A549	IC₅₀	2 μM Compound: Amonafide	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 29342415]
A549	IC₅₀	23.46 μM Compound: Amonafide	Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 33965862]
A549	IC₅₀	3.2 μM Compound: Am	Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay	[PMID: 23770449]
A549	IC₅₀	3.8 μM Compound: 1, amonafide	Antiproliferative activity against A549 cells after 72 hrs by MTT assay Antiproliferative activity against A549 cells after 72 hrs by MTT assay	[PMID: 17658777]
A549	IC₅₀	7.76 μM Compound: 1	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30774856]
A549	IC₅₀	7.94 μM Compound: Amonafide	Antiproliferative activity against human A549 cells by MTT assay Antiproliferative activity against human A549 cells by MTT assay	[PMID: 33109400]
A549	IC₅₀	8.1 μM Compound: Amonafide	Growth inhibition of human A549 cells measured after 72 hrs by SRB assay Growth inhibition of human A549 cells measured after 72 hrs by SRB assay	[PMID: 22000922]
A549	IC₅₀	9.56 μM Compound: Amonafide	Cytotoxicity against cisplatin-resistant human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against cisplatin-resistant human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 33965862]
B16-F10	IC₅₀	6.7 μM Compound: Amonafide	Cytotoxicity against mouse B16F10 cells measured after 2 days by MTS assay Cytotoxicity against mouse B16F10 cells measured after 2 days by MTS assay	[PMID: 27939348]
BT-474	IC₅₀	37.8 μM Compound: Amonafide	Cytotoxicity against human BT474 cells after 3 days by MTT assay Cytotoxicity against human BT474 cells after 3 days by MTT assay	[PMID: 24835201]
Cancer cell lines	IC₅₀	2031 nM Compound: 2	Tested against UACC375 human melanoma cancer cells by sulforhodamine B (SRB) assay Tested against UACC375 human melanoma cancer cells by sulforhodamine B (SRB) assay	[PMID: 8459403]
Ca-Ski	IC₅₀	9.96 μM Compound: Amonafide	Cytotoxicity against human CaSki cells after 3 days by MTT assay Cytotoxicity against human CaSki cells after 3 days by MTT assay	[PMID: 24835201]
CNE-2	IC₅₀	8.65 μM Compound: Amonafide	Antiproliferative activity against human CNE-2 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human CNE-2 cells assessed as cell growth inhibition by MTT assay	[PMID: 36894107]
CT26	IC₅₀	11.69 μM Compound: Amonafide	Growth inhibition of mouse CT26 cells after 24 hrs by MTT assay Growth inhibition of mouse CT26 cells after 24 hrs by MTT assay	[PMID: 29990424]
GES1	IC₅₀	21.6 μM Compound: Am	Cytotoxicity against human GES-1 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human GES-1 cells after 72 hrs by sulforhodamine B assay	[PMID: 23770449]
HCT-116	IC₅₀	15.3 μM Compound: Amonafide	Growth inhibition of human HCT116 cells measured after 72 hrs by SRB assay Growth inhibition of human HCT116 cells measured after 72 hrs by SRB assay	[PMID: 22000922]
HCT-116	IC₅₀	2.7 μM Compound: Amonafide	Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth incubated for 24 hrs by XTT assay Cytotoxicity against human HCT-116 cells assessed as inhibition of cell growth incubated for 24 hrs by XTT assay	[PMID: 30312931]
HCT-116	IC₅₀	32 μM Compound: amonafide	Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 22428910]
HCT-116	IC₅₀	4.55 μM Compound: 3, ST	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 22138307]
HCT-116	IC₅₀	6.46 μM Compound: Amonafide	Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 30151093]
HCT-116	IC₅₀	6.86 μM Compound: Amonafide	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 29133040]
HCT-116	IC₅₀	7.18 μM Compound: Amonafide	Growth inhibition of human HCT116 cells after 48 hrs by MTT assay Growth inhibition of human HCT116 cells after 48 hrs by MTT assay	[PMID: 29990424]
HCT-116	IC₅₀	8.55 μM Compound: Amonafide	Growth inhibition of human HCT116 cells after 24 hrs by MTT assay Growth inhibition of human HCT116 cells after 24 hrs by MTT assay	[PMID: 29990424]
HCT-15	IC₅₀	5.2 μM Compound: 1, amonafide	Antiproliferative activity against HCT15 cells after 72 hrs by MTT assay Antiproliferative activity against HCT15 cells after 72 hrs by MTT assay	[PMID: 17658777]
HCT-8	IC₅₀	9.26 μM Compound: Amonafide	Cytotoxicity against human HCT8 cells by MTT assay Cytotoxicity against human HCT8 cells by MTT assay	[PMID: 19643513]
HEL	IC₅₀	3.4 μM Compound: AM	Antiproliferative activity against human HEL cells after 48 hrs by MTT assay Antiproliferative activity against human HEL cells after 48 hrs by MTT assay	[PMID: 24054489]
HEL	IC₅₀	4 μM Compound: Amonafide	Antiproliferative activity against human HEL cells after 48 hrs by MTT assay Antiproliferative activity against human HEL cells after 48 hrs by MTT assay	[PMID: 28233678]
HeLa	IC₅₀	0.68 μM Compound: amonafide	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 19070496]
HeLa	IC₅₀	1.4 μM Compound: Amonafide	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 19643513]
HeLa	IC₅₀	1.4 μM Compound: amonafide	Growth inhibition of human HeLa cells by MTT assay Growth inhibition of human HeLa cells by MTT assay	[PMID: 17532640]
HeLa	IC₅₀	1.73 μM Compound: Amonafide	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 21345546]
HeLa	IC₅₀	10.67 μM Compound: Amonofide	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 20170164]
HeLa	IC₅₀	3.41 μM Compound: Amonafide	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 29342415]
HeLa	IC₅₀	4.36 μM Compound: Amonafide	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	10.1039/C5MD00543D
HeLa	IC₅₀	6.02 μM Compound: amonafide	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 21208805]
HeLa	IC₅₀	6.71 μM Compound: Amonafide	Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 24370011]
HeLa	IC₅₀	9.52 μM Compound: AM	Cytotoxicity against human HeLa cells incubated for 24 hrs by sulforhodamine B assay Cytotoxicity against human HeLa cells incubated for 24 hrs by sulforhodamine B assay	[PMID: 26211460]
HepG2	IC₅₀	1.41 μM Compound: 3, ST	Cytotoxicity against human HepG2 after 72 hrs by MTT assay Cytotoxicity against human HepG2 after 72 hrs by MTT assay	[PMID: 22138307]
HepG2	IC₅₀	1.71 μM Compound: Amonafide	Cytotoxicity against human HepG2 cells after 3 days by MTT assay Cytotoxicity against human HepG2 cells after 3 days by MTT assay	[PMID: 24835201]
HepG2	IC₅₀	10.11 μM Compound: Amonafide	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 28177238]
HepG2	IC₅₀	11.67 μM Compound: Amonafide	Growth inhibition of human HepG2 cells after 48 hrs by MTT assay Growth inhibition of human HepG2 cells after 48 hrs by MTT assay	[PMID: 29990424]
HepG2	IC₅₀	11.67 μM Compound: Amonafide	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 29133040]
HepG2	IC₅₀	36 μM Compound: amonafide	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 22428910]
HepG2	IC₅₀	6.45 μM Compound: amonafide	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 21208805]
HepG2	IC₅₀	9.38 μM Compound: Amonafide	Cytotoxicity against human HepG2 cells assessed as inhibitory of cell growth measured after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibitory of cell growth measured after 24 hrs by MTT assay	[PMID: 33965862]
HepG2	IC₅₀	9.38 μM Compound: Amonafide	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 33965862]
HepG2	IC₅₀	9.45 μM Compound: Amonafide	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 30151093]
HL-60	IC₅₀	0.9 μM Compound: Am	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 23770449]
HL-60	IC₅₀	1.63 μM Compound: amonafide	Growth inhibition of human HL60 cells by MTT assay Growth inhibition of human HL60 cells by MTT assay	[PMID: 17532640]
HL-60	IC₅₀	17.96 μM Compound: Amonofide	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 20170164]
HL-60	IC₅₀	17.96 μM Compound: Amonafide	Cytotoxicity against human HL60 cells by MTT assay Cytotoxicity against human HL60 cells by MTT assay	[PMID: 19643513]
HL-60	IC₅₀	3.4 μM Compound: Amonafide	Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay	[PMID: 28233678]
Hs 683	IC₅₀	3.9 μM Compound: 1, amonafide	Antiproliferative activity against Hs683 cells after 72 hrs by MTT assay Antiproliferative activity against Hs683 cells after 72 hrs by MTT assay	[PMID: 17658777]
HT-29	IC₅₀	5.46 μM Compound: 1	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30774856]
Huh-7	IC₅₀	8.52 μM Compound: Amonafide	Cytotoxicity against human Huh-7 cells assessed as inhibition of cell growth measured after 24 hrs by MTT assay Cytotoxicity against human Huh-7 cells assessed as inhibition of cell growth measured after 24 hrs by MTT assay	[PMID: 33965862]
Huh-7	IC₅₀	8.52 μM Compound: Amonafide	Cytotoxicity against human Huh-7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human Huh-7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 33965862]
K562	IC₅₀	> 50 μM Compound: Amonafide	Cytotoxicity against human K562 cells by MTT assay Cytotoxicity against human K562 cells by MTT assay	[PMID: 22436386]
K562	IC₅₀	10.1 μM Compound: Amonafide	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 29133040]
K562	IC₅₀	20.11 μM Compound: Amonafide	Growth inhibition of human K562 cells after 48 hrs by MTT assay Growth inhibition of human K562 cells after 48 hrs by MTT assay	[PMID: 29990424]
K562	IC₅₀	31.7 μM Compound: amonafide	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 22428910]
L02	IC₅₀	11.56 μM Compound: Amonafide	Cytotoxicity against human HL7702 cells assessed as inhibition of cell growth measured after 24 hrs by MTT assay Cytotoxicity against human HL7702 cells assessed as inhibition of cell growth measured after 24 hrs by MTT assay	[PMID: 33965862]
L02	IC₅₀	13.8 μM Compound: Am	Cytotoxicity against human LO2 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human LO2 cells after 72 hrs by sulforhodamine B assay	[PMID: 23770449]
L02	IC₅₀	5 μM Compound: Am	Cytotoxicity against human LO2 cells by SRB assay Cytotoxicity against human LO2 cells by SRB assay	[PMID: 23353750]
L1210	IC₅₀	625 nM Compound: 1	Antitumor activity against murine L1210 resistant cell line by using MTT assay Antitumor activity against murine L1210 resistant cell line by using MTT assay	[PMID: 7699715]
L1210	IC₅₀	625 nM Compound: 1	Anti-tumor activity against murine L1210 sensitive cell line by using MTT assay Anti-tumor activity against murine L1210 sensitive cell line by using MTT assay	[PMID: 7699715]
L1210	IC₅₀	625 nM Compound: 1	Tested for inhibitory activity against murine cell line L12110, a strain resistant to doxorubicin using MTT assay. Tested for inhibitory activity against murine cell line L12110, a strain resistant to doxorubicin using MTT assay.	[PMID: 10956214]
L1210	IC₅₀	625 nM Compound: 1	Tested for inhibitory activity against murine cell line L12110, a strain sensitive to doxorubicin using MTT assay. Tested for inhibitory activity against murine cell line L12110, a strain sensitive to doxorubicin using MTT assay.	[PMID: 10956214]
L1210	IC₅₀	625 nM Compound: 2	Tested against L1210 resistant murine leukemia cells by MTT tetrazolium dye assay Tested against L1210 resistant murine leukemia cells by MTT tetrazolium dye assay	[PMID: 8459403]
L1210	IC₅₀	625 nM Compound: 2	Tested against L1210 sensitive murine leukemia cells by MTT tetrazolium dye assay Tested against L1210 sensitive murine leukemia cells by MTT tetrazolium dye assay	[PMID: 8459403]
LoVo	IC₅₀	2.7 μM Compound: 1, amonafide	Antiproliferative activity against LoVo cells after 72 hrs by MTT assay Antiproliferative activity against LoVo cells after 72 hrs by MTT assay	[PMID: 17658777]
LS174T	IC₅₀	20.28 μM Compound: Amonofide	Cytotoxicity against human LS 174T cells after 72 hrs by MTT assay Cytotoxicity against human LS 174T cells after 72 hrs by MTT assay	[PMID: 20170164]
MCF7	IC₅₀	1.68 μM Compound: Amonafide	Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 24370011]
MCF7	IC₅₀	1.68 μM Compound: Amonafide	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 21345546]
MCF7	IC₅₀	10.93 μM Compound: Amonafide	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 33965862]
MCF7	IC₅₀	11.88 μM Compound: Amonofide	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 20170164]
MCF7	IC₅₀	11.88 μM Compound: Amonafide	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 19643513]
MCF7	IC₅₀	1100 nM Compound: 1	Tested for inhibitory activity against human tumor cell line MCF7, a strain sensitive to doxorubicin of breast carcinoma using sulforhodamine B assay. Tested for inhibitory activity against human tumor cell line MCF7, a strain sensitive to doxorubicin of breast carcinoma using sulforhodamine B assay.	[PMID: 10956214]
MCF7	IC₅₀	12.92 μM Compound: Amonafide	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 30151093]
MCF7	IC₅₀	1200 nM Compound: 1	Tested for inhibitory activity against human tumor cell line MCF7, a strain resistant to mitoxantrone of breast carcinoma using sulforhodamine B assay. Tested for inhibitory activity against human tumor cell line MCF7, a strain resistant to mitoxantrone of breast carcinoma using sulforhodamine B assay.	[PMID: 10956214]
MCF7	IC₅₀	1800 nM Compound: 1	Tested for inhibitory activity against human tumor cell line D40, a strain resistant to doxorubicin of breast carcinoma using sulforhodamine B assay. Tested for inhibitory activity against human tumor cell line D40, a strain resistant to doxorubicin of breast carcinoma using sulforhodamine B assay.	[PMID: 10956214]
MCF7	IC₅₀	4.05 μM Compound: 1	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30774856]
MCF7	IC₅₀	5.8 μM Compound: 1, amonafide	Antiproliferative activity against MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against MCF7 cells after 72 hrs by MTT assay	[PMID: 17658777]
MCF7	IC₅₀	6.79 μM Compound: Amonafide	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 29342415]
MCF7	IC₅₀	8.02 μM Compound: Amonafide	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	10.1039/C5MD00543D
MDA-MB-231	GI₅₀	> 25 μM Compound: AM	Growth inhibition of human MDA-MB-231 cells preincubated for 6 hrs followed compound washout measured after 24 hrs by XTT assay Growth inhibition of human MDA-MB-231 cells preincubated for 6 hrs followed compound washout measured after 24 hrs by XTT assay	[PMID: 28710962]
MDA-MB-231	GI₅₀	> 25 μM Compound: AM	Growth inhibition of human MDA-MB-231 cells preincubated for 6 hrs cotreated with chlorambucil followed compound washout measured after 24 hrs by XTT assay Growth inhibition of human MDA-MB-231 cells preincubated for 6 hrs cotreated with chlorambucil followed compound washout measured after 24 hrs by XTT assay	[PMID: 28710962]
MDA-MB-231	IC₅₀	15.23 μM Compound: Amonafide	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 33965862]
MDA-MB-231	IC₅₀	4.4 μM Compound: Am	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay	[PMID: 23770449]
MDA-MB-231	IC₅₀	42 μM Compound: amonafide	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 22428910]
MDA-MB-231	IC₅₀	6.62 μM Compound: Amonafide	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 30151093]
MDA-MB-238	IC₅₀	24.25 μM Compound: Amonafide	Cytotoxicity against human MDA-MB-238 cells assessed as cell viability measured after 96 hrs by XTT assay Cytotoxicity against human MDA-MB-238 cells assessed as cell viability measured after 96 hrs by XTT assay	[PMID: 34507011]
MGC-803	IC₅₀	3.23 μM Compound: Amonafide	Cytotoxicity against human MGC803 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MGC803 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 29342415]
MGC-803	IC₅₀	5.25 μM Compound: Amonafide	Antiproliferative activity against human MGC-803 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human MGC-803 cells assessed as cell growth inhibition by MTT assay	[PMID: 36894107]
MGC-803	IC₅₀	9.06 μM Compound: Amonafide	Antiproliferative activity against human MGC-803 cells by MTT assay Antiproliferative activity against human MGC-803 cells by MTT assay	[PMID: 33109400]
MKN-45	IC₅₀	> 50 μM Compound: Amonofide	Cytotoxicity against human MKN45 cells after 72 hrs by MTT assay Cytotoxicity against human MKN45 cells after 72 hrs by MTT assay	[PMID: 20170164]
NCI-H1299	GI₅₀	> 25 μM Compound: AM	Growth inhibition of human NCI-H1299 cells preincubated for 6 hrs followed compound washout measured after 24 hrs by XTT assay Growth inhibition of human NCI-H1299 cells preincubated for 6 hrs followed compound washout measured after 24 hrs by XTT assay	[PMID: 28710962]
NCI-H1299	GI₅₀	> 25 μM Compound: AM	Growth inhibition of human NCI-H1299 cells preincubated for 6 hrs cotreated with chlorambucil followed compound washout measured after 24 hrs by XTT assay Growth inhibition of human NCI-H1299 cells preincubated for 6 hrs cotreated with chlorambucil followed compound washout measured after 24 hrs by XTT assay	[PMID: 28710962]
NCI-H1299	IC₅₀	8.84 μM Compound: Amonafide	Cytotoxicity against human NCI-H1299 cells assessed as cell viability measured after 96 hrs by XTT assay Cytotoxicity against human NCI-H1299 cells assessed as cell viability measured after 96 hrs by XTT assay	[PMID: 34507011]
NCI-H460	IC₅₀	7.8 μM Compound: amonafide	Antiproliferative activity against human NCI-H460 cells after 72 hrs Antiproliferative activity against human NCI-H460 cells after 72 hrs	[PMID: 18061459]
OVCAR-3	IC₅₀	2180 nM Compound: 1	Anti-tumor activity against human OVCAR-3 ovarian cancer cell lines by using MTT assay Anti-tumor activity against human OVCAR-3 ovarian cancer cell lines by using MTT assay	[PMID: 7699715]
OVCAR-3	IC₅₀	2180 nM Compound: 2	Tested against OVCAR-3 human ovarian cancer cells by sulforhodamine B (SRB) assay Tested against OVCAR-3 human ovarian cancer cells by sulforhodamine B (SRB) assay	[PMID: 8459403]
OVCAR-3	IC₅₀	2180 nM Compound: 1	Tested for inhibitory activity against human tumor cell line OVCAR-3, a resistant ovarian carcinoma using sulforhodamine B assay. Tested for inhibitory activity against human tumor cell line OVCAR-3, a resistant ovarian carcinoma using sulforhodamine B assay.	[PMID: 10956214]
P388	IC₅₀	0.2 μM Compound: Am	Cytotoxicity against mouse P388 cells by tetrazolium-formazan assay Cytotoxicity against mouse P388 cells by tetrazolium-formazan assay	[PMID: 23353750]
P388	IC₅₀	0.2 μM Compound: B2	Cytotoxicity against mouse P388 cells by tetrazolium-formazan method Cytotoxicity against mouse P388 cells by tetrazolium-formazan method	[PMID: 17331719]
P388	IC₅₀	200 nM Compound: amonafide	Cytotoxicity against mouse P388 cells after 48 hrs by tetrazolium-formazan method Cytotoxicity against mouse P388 cells after 48 hrs by tetrazolium-formazan method	[PMID: 17707644]
P388	IC₅₀	200 nM Compound: Amonafide	Cytotoxic concentration against murine P388 leukemia cell line growth determined by microculture tetrazolium-formazan method Cytotoxic concentration against murine P388 leukemia cell line growth determined by microculture tetrazolium-formazan method	[PMID: 15876532]
P388	IC₅₀	4.56 μM Compound: Amonafide	Cytotoxicity against mouse P388 cells by MTT assay Cytotoxicity against mouse P388 cells by MTT assay	[PMID: 19643513]
P388	IC₅₀	4.56 μM Compound: amonafide	Growth inhibition of mouse P388 cells by MTT assay Growth inhibition of mouse P388 cells by MTT assay	[PMID: 17532640]
P388D1	IC₅₀	0.68 μM Compound: amonafide	Antiproliferative activity against mouse P388D1 cells after 48 hrs by MTT assay Antiproliferative activity against mouse P388D1 cells after 48 hrs by MTT assay	[PMID: 21208805]
P388D1	IC₅₀	6.02 μM Compound: amonafide	Cytotoxicity against mouse P388D1 cells after 48 hrs by MTT assay Cytotoxicity against mouse P388D1 cells after 48 hrs by MTT assay	[PMID: 19070496]
PANC-1	IC₅₀	2.7 μM Compound: Amonafide	Cytotoxicity against human PANC-1 cells assessed as inhibition of cell growth incubated for 24 hrs by XTT assay Cytotoxicity against human PANC-1 cells assessed as inhibition of cell growth incubated for 24 hrs by XTT assay	[PMID: 30312931]
PC-3	GI₅₀	> 25 μM Compound: AM	Growth inhibition of human PC3 cells preincubated for 6 hrs followed compound washout measured after 24 hrs by XTT assay Growth inhibition of human PC3 cells preincubated for 6 hrs followed compound washout measured after 24 hrs by XTT assay	[PMID: 28710962]
PC-3	GI₅₀	> 25 μM Compound: AM	Growth inhibition of human PC3 cells preincubated for 6 hrs cotreated with chlorambucil followed compound washout measured after 24 hrs by XTT assay Growth inhibition of human PC3 cells preincubated for 6 hrs cotreated with chlorambucil followed compound washout measured after 24 hrs by XTT assay	[PMID: 28710962]
PC-3	IC₅₀	8.05 μM Compound: 3, ST	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 22138307]
SGC-7901	IC₅₀	5.32 μM Compound: Amonafide	Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay	10.1039/C5MD00543D
SK-BR-3	IC₅₀	7.4 μM Compound: Amonafide	Antiproliferative activity against human SK-BR-3 cells after 48 hrs by MTT assay Antiproliferative activity against human SK-BR-3 cells after 48 hrs by MTT assay	[PMID: 28233678]
SK-BR-3	IC₅₀	7.4 μM Compound: AM	Antiproliferative activity against human SKBR3 cells after 48 hrs by MTT assay Antiproliferative activity against human SKBR3 cells after 48 hrs by MTT assay	[PMID: 24054489]
SK-OV-3	IC₅₀	6.31 μM Compound: Amonafide	Antiproliferative activity against human SK-OV-3 cells by MTT assay Antiproliferative activity against human SK-OV-3 cells by MTT assay	[PMID: 33109400]
SK-OV-3	IC₅₀	8.83 μM Compound: 3, ST	Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay	[PMID: 22138307]
SMMC-7721	IC₅₀	10.32 μM Compound: Amonafide	Growth inhibition of human SMMC7721 cells after 48 hrs by MTT assay Growth inhibition of human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 29990424]
SMMC-7721	IC₅₀	10.32 μM Compound: Amonafide	Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 29133040]
SMMC-7721	IC₅₀	4.15 μM Compound: amonafide	Growth inhibition of human SMMC7721 cells by MTT assay Growth inhibition of human SMMC7721 cells by MTT assay	[PMID: 17532640]
SMMC-7721	IC₅₀	4.27 μM Compound: Amonafide	Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 21345546]
SMMC-7721	IC₅₀	6.93 μM Compound: Amonafide	Antiproliferative activity against human SMMC-7721 cells by MTT assay Antiproliferative activity against human SMMC-7721 cells by MTT assay	[PMID: 33109400]
SMMC-7721	IC₅₀	9.37 μM Compound: Amonafide	Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 30151093]
SMMC-7721	IC₅₀	9.95 μM Compound: Amonafide	Cytotoxicity against human SMMC7721 cells assessed as cell growth inhibition after 48 hrs by MTT assay Cytotoxicity against human SMMC7721 cells assessed as cell growth inhibition after 48 hrs by MTT assay	[PMID: 28177238]
SW-620	IC₅₀	0.32 μM Compound: Amonafide	Cytotoxicity against human SW620 cells after 3 days by MTT assay Cytotoxicity against human SW620 cells after 3 days by MTT assay	[PMID: 24835201]
T-24	IC₅₀	5.01 μM Compound: Amonafide	Antiproliferative activity against human T-24 cells by MTT assay Antiproliferative activity against human T-24 cells by MTT assay	[PMID: 33109400]
T-24	IC₅₀	7.23 μM Compound: Amonafide	Antiproliferative activity against human T24 cells assessed as cell growth inhibition by MTT assay Antiproliferative activity against human T24 cells assessed as cell growth inhibition by MTT assay	[PMID: 36894107]
U-373MG ATCC	IC₅₀	3.5 μM Compound: 1, amonafide	Antiproliferative activity against U373MG cells after 72 hrs by MTT assay Antiproliferative activity against U373MG cells after 72 hrs by MTT assay	[PMID: 17658777]
U-87MG ATCC	IC₅₀	2.8 μM Compound: 3, ST	Cytotoxicity against human U87MG cells after 72 hrs by MTT assay Cytotoxicity against human U87MG cells after 72 hrs by MTT assay	[PMID: 22138307]
UACC-375	IC₅₀	2031 nM Compound: 1	Anti-tumor activity against human UACC375 melanoma cell lines by using MTT assay Anti-tumor activity against human UACC375 melanoma cell lines by using MTT assay	[PMID: 7699715]
UACC-375	IC₅₀	2031 nM Compound: 1	Tested for inhibitory activity against human tumor cell line UA375 of melanoma using sulforhodamine B assay. Tested for inhibitory activity against human tumor cell line UA375 of melanoma using sulforhodamine B assay.	[PMID: 10956214]
V79	IC₅₀	70.3 μM Compound: B2	Cytotoxicity against V79 cells in hypoxic condition after 24 hrs by MTT assay Cytotoxicity against V79 cells in hypoxic condition after 24 hrs by MTT assay	[PMID: 17331719]
WiDr	IC₅₀	1100 nM Compound: 1	Tested for inhibitory activity against a sensitive strain of human colon carcinoma WiDr using sulforhodamine B assay (it is MRP positive but non-P-glycoprotein). Tested for inhibitory activity against a sensitive strain of human colon carcinoma WiDr using sulforhodamine B assay (it is MRP positive but non-P-glycoprotein).	[PMID: 10956214]
WiDr	IC₅₀	2200 nM Compound: 1	Tested for inhibitory activity against a multi drug resistant (MDR) strain of human colon carcinoma WiDr using sulforhodamine B assay (it is MRP positive but non-P-glycoprotein). Tested for inhibitory activity against a multi drug resistant (MDR) strain of human colon carcinoma WiDr using sulforhodamine B assay (it is MRP positive but non-P-glycoprotein).	[PMID: 10956214]
WM 266-4	GI₅₀	> 25 μM Compound: AM	Growth inhibition of human WM266.4 cells preincubated for 6 hrs followed compound washout measured after 24 hrs by XTT assay Growth inhibition of human WM266.4 cells preincubated for 6 hrs followed compound washout measured after 24 hrs by XTT assay	[PMID: 28710962]
WM 266-4	GI₅₀	> 25 μM Compound: AM	Growth inhibition of human WM266.4 cells preincubated for 6 hrs cotreated with chlorambucil followed compound washout measured after 24 hrs by XTT assay Growth inhibition of human WM266.4 cells preincubated for 6 hrs cotreated with chlorambucil followed compound washout measured after 24 hrs by XTT assay	[PMID: 28710962]
WM 266-4	IC₅₀	6.92 μM Compound: Amonafide	Cytotoxicity against human WM 266-4 cells assessed as cell viability measured after 96 hrs by XTT assay Cytotoxicity against human WM 266-4 cells assessed as cell viability measured after 96 hrs by XTT assay	[PMID: 34507011]

體外研究
(In Vitro)

Amonafide 是一種拓?fù)洚悩?gòu)酶 II 抑制劑和 DNA 嵌入劑，可通過阻斷 Topo II 與 DNA 的結(jié)合來誘導(dǎo)細(xì)胞凋亡信號(hào)^[1]。Amonafide 產(chǎn)生蛋白質(zhì)相關(guān)的 DNA 裂解、單鏈斷裂 (SSB) 以及 DPC 和 DNA 雙鏈裂解。Amonafide (Nafidimide，400 nM-2.4 μM) 以劑量依賴性方式降低白血病細(xì)胞系的集落形成能力^[2]。Amonafide (0.05-0.4 μg/mL) 減少多種腫瘤生長(zhǎng)。然而，與標(biāo)準(zhǔn)藥物 (5-氟尿嘧啶、絲裂霉素 C、順鉑和依托泊苷) 相比，Amonafide 僅對(duì) 12% 的腫瘤具有活性，而標(biāo)準(zhǔn)藥物對(duì)人類骨髓抑制范圍內(nèi)超過 40% 的腫瘤具有活性^[3]。Amonafide 抑制 HT-29、HeLa 和 PC-3 細(xì)胞系的生長(zhǎng)，IC₅₀ 分別為 4.67、2.73 和 6.38 μM^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

283.33

Formula

C₁₆H₁₇N₃O₂

CAS 號(hào)

69408-81-7

性狀

固體

顏色

Light yellow to yellow

中文名稱

氨萘非特

運(yùn)輸條件

Room temperature in continental US; may vary elsewhere.

儲(chǔ)存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

溶解性數(shù)據(jù)

細(xì)胞實(shí)驗(yàn)：

DMSO 中的溶解度 : 41.67 mg/mL (147.07 mM; 超聲助溶; 吸濕的 DMSO 對(duì)產(chǎn)品的溶解度有顯著影響，請(qǐng)使用新開封的 DMSO)

配制儲(chǔ)備液

濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg

1 mM	3.5295 mL	17.6473 mL	35.2945 mL
5 mM	0.7059 mL	3.5295 mL	7.0589 mL
10 mM	0.3529 mL	1.7647 mL	3.5295 mL

查看完整儲(chǔ)備液配制表

* 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲(chǔ)備液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?年內(nèi)使用， -20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?年內(nèi)使用。

摩爾計(jì)算器
稀釋計(jì)算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

濃度 _(start)

體積 _(start)

濃度 _(final)

體積 _(final)

動(dòng)物實(shí)驗(yàn)：

請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥方式選擇適當(dāng)?shù)娜芙夥桨浮?

以下溶解方案都請(qǐng)先按照 In Vitro 方式配制澄清的儲(chǔ)備液，再依次添加助溶劑：
——為保證實(shí)驗(yàn)結(jié)果的可靠性，澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

方案一

請(qǐng)依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.82 mM); 澄清溶液

此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液。
以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水定容至 1 mL。
生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
方案二

請(qǐng)依序添加每種溶劑： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (7.34 mM); 懸濁液; 超聲助溶

此方案可獲得 2.08 mg/mL的均勻懸濁液，懸濁液可用于口服和腹腔注射。
以 1 mL 工作液為例，取 100 μL 20.8 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液中，混合均勻。
2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。

動(dòng)物溶解方案計(jì)算器

請(qǐng)輸入動(dòng)物實(shí)驗(yàn)的基本信息：

給藥劑量

mg/kg

動(dòng)物的平均體重

每只動(dòng)物的給藥體積

μL

動(dòng)物數(shù)量

只

由于實(shí)驗(yàn)過程有損耗，建議您多配一只動(dòng)物的量

請(qǐng)輸入您的動(dòng)物體內(nèi)配方組成：

DMSO +

Tween-80 +

Saline

如果您的動(dòng)物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。

方案所需 助溶劑 包括：DMSO，，均可在 MCE 網(wǎng)站選購(gòu)。，Tween 80，均可在 MCE 網(wǎng)站選購(gòu)。

計(jì)算結(jié)果

工作液所需濃度 : mg/mL

儲(chǔ)備液配制方法 : mg 藥物溶于 μL DMSO（母液濃度為 mg/mL）。

您所需的儲(chǔ)備液濃度超過該產(chǎn)品的實(shí)測(cè)溶解度，以下方案僅供參考，如有需要，請(qǐng)與 MCE 中國(guó)技術(shù)支持聯(lián)系。

動(dòng)物實(shí)驗(yàn)體內(nèi)工作液的配制方法 : 取 μL DMSO 儲(chǔ)備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。

連續(xù)給藥周期超過半月以上，請(qǐng)謹(jǐn)慎選擇該方案。

請(qǐng)確保第一步儲(chǔ)備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱（超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。

純度 & 產(chǎn)品資料

純度: 99.92%

選擇批次：

Data Sheet (646 KB) SDS (392 KB)

COA (291 KB) HNMR (200 KB) LCMS (122 KB) Others (70 KB)

產(chǎn)品使用指南 (1538 KB)

參考文獻(xiàn)

[1]. Allen SL, et al. Amonafide: a potential role in treating acute myeloid leukemia. Expert Opin Investig Drugs. 2011 Jul;20(7):995-1003. [Content Brief]

[2]. Andersson BS, et al. In vitro toxicity and DNA cleaving capacity of benzisoquinolinedione (nafidimide; NSC 308847) in human leukemia. Cancer Res. 1987 Feb 15;47(4):1040-4. [Content Brief]

[3]. Ajani JA, et al. In vitro activity of amonafide against primary human tumors compared with the activity of standard agents. Invest New Drugs. 1988 Jun;6(2):79-85. [Content Brief]

Cell Assay ^[2]	In experiments measuring survival following 1 h drug treatments, 2 × 10⁶cells are resuspended in 2 mL warm (37°C) HBSS with 5% PCS; the appropriate drug (Amonafide) level is attained with the addition of less than 50 μL. Cells are incubated for 60 min at 37°C after which 10 mL ice cold PBS is added. The cells are then centrifuged at 200 × g for 10 min at 4°C. The wash is repeated once and the cells are resuspended in HBSS with 5% PCS and added to the agar-medium mixture for assessment of surviving clonogenic cells^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
參考文獻(xiàn)	[1]. Allen SL, et al. Amonafide: a potential role in treating acute myeloid leukemia. Expert Opin Investig Drugs. 2011 Jul;20(7):995-1003. [Content Brief] [2]. Andersson BS, et al. In vitro toxicity and DNA cleaving capacity of benzisoquinolinedione (nafidimide; NSC 308847) in human leukemia. Cancer Res. 1987 Feb 15;47(4):1040-4. [Content Brief] [3]. Ajani JA, et al. In vitro activity of amonafide against primary human tumors compared with the activity of standard agents. Invest New Drugs. 1988 Jun;6(2):79-85. [Content Brief]

Cell Assay
^[2]

In experiments measuring survival following 1 h drug treatments, 2 × 10⁶cells are resuspended in 2 mL warm (37°C) HBSS with 5% PCS; the appropriate drug (Amonafide) level is attained with the addition of less than 50 μL. Cells are incubated for 60 min at 37°C after which 10 mL ice cold PBS is added. The cells are then centrifuged at 200 × g for 10 min at 4°C. The wash is repeated once and the cells are resuspended in HBSS with 5% PCS and added to the agar-medium mixture for assessment of surviving clonogenic cells^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

參考文獻(xiàn)

[1]. Allen SL, et al. Amonafide: a potential role in treating acute myeloid leukemia. Expert Opin Investig Drugs. 2011 Jul;20(7):995-1003. [Content Brief]

[2]. Andersson BS, et al. In vitro toxicity and DNA cleaving capacity of benzisoquinolinedione (nafidimide; NSC 308847) in human leukemia. Cancer Res. 1987 Feb 15;47(4):1040-4. [Content Brief]

[3]. Ajani JA, et al. In vitro activity of amonafide against primary human tumors compared with the activity of standard agents. Invest New Drugs. 1988 Jun;6(2):79-85. [Content Brief]

Amonafide 相關(guān)分類

完整儲(chǔ)備液配制表

可選溶劑	濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.5295 mL	17.6473 mL	35.2945 mL	88.2363 mL
	5 mM	0.7059 mL	3.5295 mL	7.0589 mL	17.6473 mL
	10 mM	0.3529 mL	1.7647 mL	3.5295 mL	8.8236 mL
	15 mM	0.2353 mL	1.1765 mL	2.3530 mL	5.8824 mL
	20 mM	0.1765 mL	0.8824 mL	1.7647 mL	4.4118 mL
	25 mM	0.1412 mL	0.7059 mL	1.4118 mL	3.5295 mL
	30 mM	0.1176 mL	0.5882 mL	1.1765 mL	2.9412 mL
	40 mM	0.0882 mL	0.4412 mL	0.8824 mL	2.2059 mL
	50 mM	0.0706 mL	0.3529 mL	0.7059 mL	1.7647 mL
	60 mM	0.0588 mL	0.2941 mL	0.5882 mL	1.4706 mL
	80 mM	0.0441 mL	0.2206 mL	0.4412 mL	1.1030 mL
	100 mM	0.0353 mL	0.1765 mL	0.3529 mL	0.8824 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Amonafide69408-81-7AS1413氨萘非特AS 1413AS-1413TopoisomeraseInhibitorinhibitorinhibit

產(chǎn)品名稱：			* 需求量：
* 客戶姓名：			* Email：
* 電話：			* 公司或機(jī)構(gòu)名稱：
留言給我們：

產(chǎn)品名稱：			* Lot #：
* 客戶姓名：			* Email：
電話：			* 部門：
* 公司或機(jī)構(gòu)名稱：
留言給我們：

MedChemExpress (MCE) 只為有資質(zhì)的科研機(jī)構(gòu)、醫(yī)藥企業(yè)基于科學(xué)研究或藥證申報(bào)的用途提供醫(yī)藥研發(fā)服務(wù)，不為任何個(gè)人或者非科研性質(zhì)的、非用于藥證申報(bào)使用等其他用途提供服務(wù)。	站點(diǎn)地圖隱私聲明
滬ICP備15051369號(hào)-4 上海工商滬公網(wǎng)安備31011502019417 滬(浦)應(yīng)急管危經(jīng)許[2021]201709(QFYS) 營(yíng)業(yè)執(zhí)照（三證合一）
Copyright ? 2013-2025 MedChemExpress. All Rights Reserved.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Amonafide (Synonyms: 氨萘非特; AS1413)

Customer Review

Other Forms of Amonafide:

MCE 顧客使用本產(chǎn)品發(fā)表的 3 篇科研文獻(xiàn)

Amonafide 相關(guān)產(chǎn)品

•相關(guān)化合物庫(kù):

•同靶點(diǎn)產(chǎn)品:

•同靶點(diǎn)蛋白產(chǎn)品:

查看 Topoisomerase 亞型特異性產(chǎn)品:

生物活性

實(shí)驗(yàn)參考方法

純度 & 產(chǎn)品資料

參考文獻(xiàn)

摩爾計(jì)算器

稀釋計(jì)算器

Amonafide 相關(guān)分類

完整儲(chǔ)備液配制表

Keywords:

您最近查看的產(chǎn)品:

熱門區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
郵箱 *

Sorry, but the email address you supplied was invalid.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Amonafide (Synonyms: 氨萘非特; AS1413)

Customer Review

Other Forms of Amonafide:

Amonafide 相關(guān)抗體

MCE 顧客使用本產(chǎn)品發(fā)表的 3 篇科研文獻(xiàn)

Amonafide 相關(guān)產(chǎn)品

•相關(guān)化合物庫(kù):

•同靶點(diǎn)產(chǎn)品:

•同靶點(diǎn)蛋白產(chǎn)品:

查看 Topoisomerase 亞型特異性產(chǎn)品:

生物活性

實(shí)驗(yàn)參考方法

純度 & 產(chǎn)品資料

參考文獻(xiàn)

Amonafide 相關(guān)抗體:

摩爾計(jì)算器

稀釋計(jì)算器

Amonafide 相關(guān)分類

完整儲(chǔ)備液配制表

Keywords:

您最近查看的產(chǎn)品:

Request for HNMR Report

Request for HNMR Report

熱門區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z